There are no discussions yet.

  • Disease Description

    Melanoma is considered the most dangerous form of skin cancer. These cancerous growths develop when unrepaired DNA damage to skin cells (most often caused by ultraviolet radiation from sunshine or tanning beds) triggers mutations (genetic defects) that lead the skin cells to multiply rapidly and form malignant tumors. These tumors originate in cells called melanocytes. Melanocytes are the cells responsible for giving our skin their color. Melanomas often resemble moles; some develop from moles. The majority of melanomas are black or brown, but they can also be skin-colored, pink, red, purple, blue or white. Melanoma is caused mainly by intense, occasional UV light exposure (frequently leading to sunburn), especially in those who are genetically predisposed to the disease. [1]


    Prevelance


    Melanoma is the fifth most common cancer in men and seventh in women in the United States. The number of melanoma cases is increasing faster than for any other type of cancer. Estimates for 2014 are that 76,100 invasive melanomas will be diagnosed in the United States and that melanoma could claim 9710 lives [2].


    Current Treatment Options


    At present, prevention and early detection are the only effective measures against melanoma. Melanoma basically remains a surgical disease, and excision of thin, biologically early tumors offers the best chance of cure. Despite intensive research, no effective therapies exist for advanced melanoma. Only high-dose IFN -2b has a reproducible benefit in stage II and III patients, but owing to its numerous side effects, modest efficacy, and high cost, it is not used worldwide and is inconsistently used in the United States. For patients with stage IV melanoma, randomized, controlled trials have shown no significant advantage of any specific drug or combination of drugs. Dacarbazine, the only cytotoxic drug approved by the FDA for the treatment of metastatic melanoma, remains the benchmark, but it produces responses of moderate duration and only in a small fraction of the patients. New therapeutic strategies are therefore necessary for the management of melanomas.[3]


    Evidence for and the Proposed Mechanism of Cannabinoid Therapeutics


    Accumulating recent evidence implicates the endocannabinoid system in the regulation of growth of skin cells. Cannabinoids were also reported to inhibit the growth of melanomas that express cannabinoid receptors (CB1 and CB2) by decreasing growth, proliferation, blood vessel growth and metastasis formation, while increasing cell death. [4]


    Groups have studied the potential efficacy of cannabinoids as antitumoral agents against melanoma and showed that these compounds exert a remarkable growth-inhibiting effect on melanoma cells that is evident under various experimental settings (animals with different immune statuses, melanoma cells inoculated at different sites, cannabinoids injected by different routes). Moreover, this is associated with an improvement of various tumor-progression parameters (decreased proliferation and vascularization, increased cell death), as well as with an inhibition of tumor-cell metastatic spreading, one of the clinical hallmarks of advanced melanoma.[5]


    Together with the implication of cannabinoid receptors (CB2) in the control of processes such as pain initiation, emesis, and inflammation, opens the attractive possibility of finding cannabinoid-based therapeutic strategies devoid of nondesired psychotropic side effects. Specifically, the antiproliferative effect of cannabinoids reported may set the basis for a new therapeutic approach for the treatment of malignant melanoma.[5]


    1. Skin Cancer Foundation. www.skincancer.org/


    2. National Cancer Institute. http://seer.cancer.gov/statfacts/html/melan.html


    3. Blazquez, C. et al. (2006) Cannabinoid receptors as novel targets for the treatment of melanoma. FASEB J. 20, 2633–2635


    4. Pacher, P. et al. The endocannabinoid system of the skin in health and disease: novel perspectives and therapeutic opportunities. Trends Pharmacol Sci. Aug 2009; 30(8): 411–420.


    5.Blazquez, C. et al. (2006) Cannabinoid receptors as novel targets for the treatment of melanoma. FASEB J. 20, 2633–2635

  • Category
    Critical Ailments
  • Created
    Thursday, 16 March 2017
  • Group admin
    CBIS

American States University

 CSi_Updates_Outline2.jpgDrug Valuation Image3


 

 Recent GBXI News:

June 22, 2023, GBX International Group, Inc., (OTC: GBXI)
Breaking Cancer Barriers; Investments in Low-Cost, Harvard Award-Winning, Effective Cancer Killing Drugs Now; GBXI Proceeds to Raise $1 Million to Fast-Track its' Success, Cancer Drug Valuations, Access for Patients, Full Company Audit, and Accelerate the Trading of the CSi-Spinout Shares

 

May 11, 2023, GBX International Group, Inc., (OTC: GBXI)
GBX International Group, Inc. (OTC:GBXI) Confirms 2023 Strong Revenue Growth Guidance Projections by Combining Each Acquired Operating Company Product Release, Expects Strong Growth Sector by Sector Through its Multiple Product Releases into North American and International Markets


April 21, 2023, GBX International Group, Inc., (OTC: GBXI)

HARVARD Award Winning Entrepreneur, Mr. Raymond C. Dabney Acquires Majority Shareholder Control of GBX International Group, Inc. (OTC: GBXI) Makes More History Bringing CSi-EDP Partner American States University (ASU) as the First Acquisition for its Aggressive Growth Plans 



Harvard GHC Award RCD 2018

 

The ASU Digital Business HUB will be used as the main business student learning center. GBXI will be the main pivot point to spin out trading shares of all our Partner Public and Private Companies such as Cannabis Science, iCannabinoid, Thermic Science, LNC, LMG, and a few more old and new school surprises for our loyal shareholders. No one will be missed! A true Digital Business HUB for students, just as planned all along.

Each spinout company will give our GBXI registered shareholders additional pro-rata shares in each spinout company over and above their original shares in each entity. This provides the required shareholder base for each company required to trade and gives additional shares to all our loyal GBXI shareholders.

We call this “Compounding our Wealth” through extra spinout share participation for all our loyal GBXI shareholders. Each registered GBXI shareholder will receive additional shares of each spinout Company over and above their original shares to enjoy additional liquidity as each company begins to trade through the GBXI Digital Business HUB spinout process.

 

Click here to review the Report:

Frontiers Capture
1mmStrong July 8 Court UPDATE Brochure Image

Sac Court Capture

Case No. 2:17-CV-02271-KJM-JDP



Inspire, Dream, Change

YOUR DIGITAL ERA Personal & Business Access Learning HUB
 



Observational Studies

PART

Activity Stream

Hello Raymond,
Anything new and exciting for to report on our progress? Curious minds want to know! We should start trading soon I would hope...
Show more

Raymond C. Dabney Hey Mike good morning! Hope all is well for you! Sorry for the delayed response I know this is your second poke! Once again, it's been crazy busy... Show more 2 days ago
loader
loader
Attachment
Tim Hofman Woot woot! Trains a coming! yesterday
loader
loader
Attachment
Raymond C. Dabney Cheers Guys! It has certainly been a long time coming. As they say "Good Things" do come to those who "work and wait" for it. We certainly know "how... Show more yesterday
loader
loader
Attachment
Raymond C. Dabney Once Again, Thanks for reading our updates Guys! That is correct we are ALL waiting patiently for the same stock exchange approval process.

Not sure...
Show more
yesterday
loader
loader
Attachment

Hi Raymond,

As a long-standing Loyal Shareholder, I hope that this posting finds you in good health and good spirits. I made my first CBIS purchase...
Show more

Alvin Kline So the shares that we have sitting idle are going to stay with the price of whatever's it's at which isn't much the last time I looked we're going... Show more 2 days ago
loader
loader
Attachment
Tim Maddox i had 2000 shares cbis stock ??? yesterday
loader
loader
Attachment
Tim Maddox where did it disappear to yesterday
loader
loader
Attachment
loader
loader
Attachment
Raymond C. Dabney Once again, Anyone who can not "Find" their shares should get an "Official Letter" from their Brokerage Firm confirming what they did with them and... Show more yesterday
loader
loader
Attachment

Cannabis Science Inc. "Shareholder Loyalty Gift Center of Excellence"

HARVARD Award Winning 
CANCER Killing Success





1st HARVARD Award Winning
Stage 4 Lung Cancer Killing Article:
*** Please click image below.

Frontiers_1.JPG


2nd HARVARD Award Winning
Stage 4 Lung Cancer Killing Article:
*** Please click image below.

 Frontiers_2.JPG


*** PLUS

(3) other Cannabis Science
REAL WORLD Successes:

Stage 4 Breast Cancer

WhatsApp_Image_2022-05-21_at_9.37.37_AM_3.jpg
Skin Cancer 

WhatsApp_Image_2022-05-21_at_9.37.38_AM.jpeg
Karposis Sarcoma

WhatsApp_Image_2022-05-21_at_9.37.38_AM_1.jpeg

CSi Final GIFT Share Issuance Nov 27 2022



Cannabis Science CEO, Presents …

The FINAL “CBIS GIFT Shares” Issuances!

DECEMBER 1, 2022, Cheers! & HAPPY HOLIDAYS !!!

ALL GIFT Shares 1, 2, & 3 being ISSUED !!!

 LAST Steps:

Please confirm Yours NOW !!!

1. CONFIRM Correct Total Share Amount(s)

2. CONFIRM Correct Name(s) on CERTIFICATE

3. CONFIRM Correct Mailing Address

ASU/CSi-EDP-ECO-System
At it's FINEST !!! 

WHICH ONE ARE YOU ??

Those who, MAKE things happen.
Those who WATCH things happen.
Those who WONDER what the ... HAPPENED ???

We can make this HAPPEN way FASTER Working as a TEAM !!!

WHAT Matters is how much you CARE about KILLING CANCERS ...

This is it ... We are ALL Here ... Now ... with a Bunch of Celebrities going on TV Worldwide to Start raising $20 Million to Keep Killing Cancers.



2023 Audit considerations NASDAQ.

Cannabis Science Inc.
Share Structure 2023

Par Value: $0.001 USD
Last Price: $0.00647 USD
OTC Markets.

Common Stock:
Authorized:
5,000,000,000
Issued:
2,521,095,296

Class A Common Stock
Authorized:
100,000,000
Issued:
0

Class B Common Stock
Authorized:
1,500,000,000
Issued:
0

Preferred Stock
Authorized:
1,000,000
Issued:
1,000,000



Sign up for a FREE Assessment to JOIN the UNIVERSITY Team or any ASU/CSi-EDP Team for whatever your AREA of Expertise is … then say no more… you already know.

You already know our Extensive LIST of GROUNDBREAKING Products.

1-Million STRONG TV Coverage, HARVARD Award Success.

TAKE YOUR PICK AND BECOME A PART OF HISTORICAL CHANGE




*** APPLY for FREE in CONFIDENCE and Success.

Each Product launch WE RELEASE will include Equity Participation according to standard salaries and share bonus structures.

EVERYONE sign up to add your STRENGTHS to OUR COMBINED SUCCESS and lets MAKE THIS HAPPEN NOW !!!